Walleye Capital LLC Raises Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)

Walleye Capital LLC increased its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 263.5% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 67,609 shares of the biopharmaceutical company’s stock after acquiring an additional 49,009 shares during the quarter. Walleye Capital LLC owned approximately 0.06% of Fate Therapeutics worth $237,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets increased its stake in Fate Therapeutics by 1,307.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 174,148 shares of the biopharmaceutical company’s stock worth $610,000 after buying an additional 161,776 shares during the period. FMR LLC increased its stake in Fate Therapeutics by 25.9% in the 3rd quarter. FMR LLC now owns 227,981 shares of the biopharmaceutical company’s stock valued at $798,000 after buying an additional 46,892 shares during the period. Intech Investment Management LLC bought a new stake in Fate Therapeutics in the third quarter worth approximately $108,000. Thrivent Financial for Lutherans boosted its holdings in shares of Fate Therapeutics by 24.7% during the 3rd quarter. Thrivent Financial for Lutherans now owns 125,370 shares of the biopharmaceutical company’s stock worth $439,000 after buying an additional 24,804 shares during the period. Finally, Privium Fund Management B.V. bought a new stake in Fate Therapeutics in the 3rd quarter valued at $175,000. Institutional investors and hedge funds own 97.54% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on FATE. Wedbush reiterated a “neutral” rating and set a $5.00 target price on shares of Fate Therapeutics in a research report on Tuesday, November 12th. Bank of America raised shares of Fate Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday, November 18th. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a report on Tuesday, November 19th. Finally, HC Wainwright reiterated a “neutral” rating and issued a $5.00 price objective on shares of Fate Therapeutics in a report on Thursday, August 22nd. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $6.75.

Fate Therapeutics Stock Performance

FATE stock opened at $2.28 on Wednesday. The company’s 50-day simple moving average is $2.73 and its 200 day simple moving average is $3.42. Fate Therapeutics, Inc. has a 52 week low of $1.96 and a 52 week high of $8.83. The company has a market capitalization of $259.67 million, a PE ratio of -1.38 and a beta of 1.95.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.02. The firm had revenue of $3.07 million for the quarter, compared to the consensus estimate of $0.88 million. Fate Therapeutics had a negative net margin of 1,325.43% and a negative return on equity of 45.88%. On average, analysts forecast that Fate Therapeutics, Inc. will post -1.72 EPS for the current year.

Fate Therapeutics Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.